← Back to Search

Imaging Biomarker

PET/MR with 18F-FDG for Pulmonary Hypertension

N/A

Recruiting

Led By Patrick Veit-Haibach, MD

Research Sponsored by University Health Network, Toronto

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Intention to treat with radio(chemo)therapy with incidental cardiac irradiation of at least 25Gy.

Biopsy or otherwise clinically proven thoracic malignant mass which is intended to be treated with radio(chemo)therapy

Timeline

Screening 3 weeks

Treatment Varies

Follow Up at 4 weeks prior to radiotherapy, and at 6-10 weeks after completion of radiotherapy

Awards & highlights

Study Summary

This trial will help to improve the understanding of the pathophysiology of RT-induced cardiopulmonary dysfunction and to develop new biomarkers for early diagnosis and risk stratification.

Who is the study for?

This trial is for adults over 18 with a diagnosed thoracic cancer intended to be treated with radiotherapy that also affects the heart. They must consent to PET/MR imaging, blood tests, and not be pregnant if of child-bearing age.Check my eligibility

What is being tested?

The study is testing how well PET/MR imaging combined with blood analysis can predict heart and lung problems after radiotherapy in patients at risk of developing pulmonary hypertension (high blood pressure in lungs).See study design

What are the potential side effects?

While the trial itself may not have direct side effects, potential risks include discomfort from the PET/MR procedure and reactions related to contrast agents used during imaging.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am planning to undergo radiation therapy that will affect my heart.

Select...

My chest tumor will be treated with radiation or chemo.

Select...

I am 18 years old or older.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ at 4 weeks prior to radiotherapy, and at 6-10 weeks after completion of radiotherapy

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~at 4 weeks prior to radiotherapy, and at 6-10 weeks after completion of radiotherapy

This trial's timeline: 3 weeks for screening, Varies for treatment, and at 4 weeks prior to radiotherapy, and at 6-10 weeks after completion of radiotherapy for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Change of FDG uptake of heart

Change of FDG uptake of lungs

Change of the heart function

+1 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: One arm / exploratory studyExperimental Treatment1 Intervention

Injection of 18F-FDG.The 18F-FDG cardiac PET-MR scanning visit will take up to 1.5 hours.

0 / 3Eligibility criteria met

Find a Location

Who is running the clinical trial?

University Health Network, TorontoLead Sponsor

1,474 Previous Clinical Trials

485,002 Total Patients Enrolled

Patrick Veit-Haibach, MDPrincipal InvestigatorUniversity Health Network, Toronto

7 Previous Clinical Trials

366 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What other research has been conducted to analyze the effects of PET/MR with 18F-FDG?

"Currently, 18 clinical studies are in progress studying PET/MR with 18F-FDG. One of these trials is currently Phase 3 and 19 locations across Warsaw Mazovian have been established to conduct research on this medicinal therapy."

Answered by AI

How many participants are currently engaged with this trial?

"Affirmative. According to clinicaltrials.gov, the trial is still actively recruiting patients and was initially posted on June 1st 2021. Recently updated on September 29th 2021, this research project requires 40 individuals from a single medical centre for participation."

Answered by AI

What medical applications does PET/MR with 18F-FDG typically have?

"PET/MR with 18F-FDG is an effective course of treatment for seizures and epilepsy, along with coronary artery disease (CAD), malignancies, and other positron emission tomography afflictions."

Answered by AI

Is there availability for participants to join the clinical trial?

"Confirmed. Details found on clinicaltrials.gov signify that this medical study, first posted in June 2021, is actively recruiting patients at the moment. Approximately 40 individuals must be enrolled from a single location."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

PET/MR Pre- and Post Radiotherapy for Cardiopulmonary Dysfunction Evaluation

2021. "PET/MR Pre- and Post Radiotherapy for Cardiopulmonary Dysfunction Evaluation". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04901884.

All > Pulmonary Hypertension